Analystreport

CytomX Therapeutics, Inc. (NASDAQ: CTMX) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $2.00 price target on the stock.

CytomX Therapeutics, Inc.  (CTMX) 
Last cytomx therapeutics, inc. earnings: 11/7 04:09 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.cytomx.com